2026202520242023202220212020

2026 Issuances

• HTA Council Preliminary Recommendation on abiraterone acetate 500mg film-coated tablet as first-line treatment or second-line treatment for metastatic castration-resistant prostate cancer (mCRPC)
  July 8, 2026
• HTA Council Preliminary Recommendation on ceftazidime/avibactam [2g/0.5g powder for concentrate for solution for infusion] and ceftolozane/tazobactam [1g/0.5g powder for concentrate for solution for infusion] for Adult Hospitalized Patients ≥18 years with Hospital-Acquired Pneumonia (HAP) or Ventilator-Acquired Pneumonia (VAP)
  July 7, 2026
• HTA Council Final Recommendation on Pneumococcal Vaccines for the Prevention of Diseases caused by Streptococcus pneumoniae in Adults 60 years old and above (with Secretary of Health Decision)
  June 22, 2026
• HTA Council Preliminary Recommendation on norepinephrine (as tartrate) 1mg/mL concentrate solution for IV infusion in 8mL ampule for cardiogenic or vascular shock that persists after adequate fluid volume replacement; severe hypotension; and, (as first-choice vasopressor) treatment of sepsis and septic shock in adults
  June 16, 2026
• HTA Council Preliminary Recommendation on levothyroxine sodium 12.5 micrograms (mcg) and 25 mcg tablets for the management of hypothyroidism of any etiology
  June 16, 2026
• HTA Council Final Recommendation on Multiple Micronutrient Supplement (MMS) film-coated tablet for the prevention of vitamin and mineral deficiencies, improvement of iron status, and reduction of anemia among pregnant and lactating women (with Secretary of Health Decision)
  June 3, 2026
• HTA Council Final Recommendation on Epidermal Growth Factor Receptor (EGFR) Polymerase Chain Reaction (PCR) mutation test for the diagnosis of EGFR Mutations in patients with Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
  May 11, 2026
• HTA Council Final Recommendation on erlotinib (25 mg, 100 mg, and 150 mg film-coated tablet), gefitinib (250 mg tablet and film-coated tablet), and afatinib (20 mg, 30 mg, and 40 mg film-coated tablet) for the treatment of Epidermal Growth Factor Receptor (EGFR) mutation – postitive Non-Small Cell Lung Cancer (NSCLC) (with Secretary of Health Decision)
  May 11, 2026
• HTA Council Final Recommendation on Atezolizumab [60 mg/mL, 20 mL vial for Intravenous (IV) Infusion] + Bevacizumab [25 mg/mL, 4 mL or 16 mL vial for Intravenous (IV) Infusion] and Lenvatinib [4 mg or 10 mg capsule] for adults diagnosed with advanced or unresectable Hepatocellular Carcinoma (uHCC) (with Secretary of Health Decision)
  May 7, 2026
• HTA Council Final Recommendation on meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine for active immunization of individuals from the age of 6 weeks against invasive meningococcal diseases caused by Neisseria meningitidis groups A, C, W-135 and Y (with Secretary of Health decision)
  May 7, 2026
• HTA Council Final Recommendation on Thermal Ablation for the treatment of premalignant lesions of the cervix among women 30 to 65 years old who are deemed eligible for ablation in accordance to the World Health Organization (WHO) screen-treat approach or screen-triage-treat approach (with Secretary of Health Decision)
  May 7, 2026
• HTA Council Final Recommendation on aflibercept [40mg/mL solution for intravitreal injection], ranibizumab [10 mg/mL solution for intravitreal injection], and dexamethasone [700 mcg intravitreal implant] for the treatment of retinal diseases (with Secretary of Health Decision)
  May 7, 2026
• HTA Council Final Recommendation on Rotavirus Vaccine (live, attenuated) monovalent G1P[8] strain Porcine Circovirus (PCV)-free for the prevention of gastroenteritis caused by rotavirus infection in children less than one (1) year of age (with Secretary of Health Decision)
  May 7, 2026
• HTA Council Final Recommendation on Biannual Ultrasound (US) combined with Alphafetoprotein (AFP) test as screening test for adults at high risk to develop Hepatocellular Carcinoma (HCC) (with Secretary of Health Decision)
  May 7, 2026
• HTA Council Final Recommendation on Moderate Complexity Nucleic Acid Amplification Tests   (NAATS) for the diagnosis of Multi-drug Resistant Tuberculosis (MDR-TB) with isoniazid (INH) and rifampicin (RIF) resistance testing (with Secretary of Health Decision)
  May 7, 2026
• CALL FOR EXPRESSION OF INTEREST: HTA Research Agenda Program [HTA Research Topics 2026 – Batch 2] [CLOSED]
  May 5, 2026
• HTA Council Final Recommendation on Reteplase (10 units lyophilized powder for IV injection) for ST-Elevation Myocardial Infarction Patients
  April 13, 2026
• HTA Council Final Recommendation on Cerebrolysin [215.2 mg/ml, 10ml ampule for IV infusion] for the Treatment of adults with Post-Ischemic Stroke
  April 13, 2026
• HTA Council Final Recommendation on Ticagrelor (90mg film-coated tablet) as an add-on to aspirin for adults with Acute Coronary Syndrome (ACS)
  January 19, 2026
• HTA Council Final Recommendation on Ceftaroline fosamil (600 mg powder for concentrate for solution for injection) for the treatment of community-acquired pneumonia (CAP) in the pediatric population
  January 18, 2026

2025 Issuances

• CALL FOR EXPRESSION OF INTEREST: HTA Research Agenda Program [HTA Research Topics 2025 – Batch 1] [CLOSED]
  October 10, 2025
• HTA Council Preliminary Recommendation Pneumococcal Conjugate Vaccines (PCV) for elderly adults 60 years old and above
  September 19, 2025

2024 Issuances

• HTA Council Recommendation on Calcium Hydroxide 80% + Clinoptilolite 20% (Kiti-kitiX) Larvicide
  September 10, 2024
• [Advisory] Release of HTA Topic Prioritization List 2024 – Cycle 2 Topics that will proceed to Topic Assessment
  May 24, 2024
• [Advisory] Release of the Provisional TP List (April 2024)
  April 17, 2024

2023 Issuances

• HTAC Guidance: PNF Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe
  March 14, 2023
• HTAC Guidance: PNF Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe
  March 14, 2023
• [Announcement] Ceremonial Turnover of HTA Implementation from the Department of Health to the Department of Science and Technology
  March 9, 2023
• [Department Circular No. 2023-0059] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Deferasirox 90 mg and 180 mg Film-Coated Tablet (FCT) for Chronic Iron Overload due to Repetitive Blood Transfusions in Patients 2 Years Old and Above in the Philippine National Formulary (PNF)
  February 13, 2023
• [Department Circular No. 2023-0061] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Filgrastim 300 mcg/0.9 mL Solution (IV, SC), 0.9 mL Pre-filled Syringe for the Treatment of Neutropenia in Patients Undergoing Bone Marrow Transplantation and Patients Receiving Myelosuppressive Cancer Chemotherapy in the Philippine National Formulary (PNF)
  February 13, 2023
• [DC No. 2023-0060] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Recombinant Human Erythropoietin (Epoetin Alfa) 4000 IU/mL Solution for Injection (IV/SC) 1mL Pre-filled Syringe for the Management of Chemotherapy-Induced Anemia in Patients with Non-Myeloid Disease in the Philippine National Formulary (PNF)
  February 13, 2023

2022 Issuances

• [Advisory] Extension of the Call for Nominations to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members until 27 January 2023
  December 22, 2022
• [Department Circular No. 2022 – 0625] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Abiraterone Acetate and Non-Inclusion of Enzalutamide for Individuals with Metastatic Castration-Resistant Prostate Cancer in the Philippine National Formulary (PNF)
  December 15, 2022
• [Department Memorandum No. 2022 – 0545] Interim Guidelines on the Process and Methods for the Selection of Medical Devices for Inclusion in the Philippine Essential Medical Device List (PEMDL)
  December 14, 2022
• [Advisory] Publication of the Guidelines on the Application of the Philippine Social Values on the Health Technology Assessment (HTA)
  December 13, 2022
• [Advisory] Extension of the Call for Nominations to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members until 07 December 2022
  November 14, 2022
• [Department Personnel Order No. 2022 – 3735] Appointment of the Health Technology Assessment Council Core and Subcommittees
  November 10, 2022
• [Department Circular No. 2022 – 0584] Amendment to the Department Circular 2022-0254 dated 05 April 2022 titled, “Updates on the HTAC Processing of Minor Inclusion”
  November 9, 2022
• [Department Circular No. 2022 – 0580] Release of the Final Priority List of HTA Topics for 2022 That Will Proceed to Topic Assessment
  November 7, 2022
• [Department Circular No. 2022 – 0560] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Zoledronic Acid for Individuals with Malignancy-Related Bone Disease in the Philippine National Formulary (PNF)
  October 28, 2022
• [Department Personnel Order No. 2022 – 3725] Appointment of the Health Technology Assessment Council Core and Subcommittees
  October 20, 2022
• [Department Circular No. 2022 – 0537] Health Technology Assessment Council (HTAC) Recommendation for the Inclusion of Insulin Glargine and Non inclusion of Insulin Detemir for Patients with Type 1 or Type 2 Diabetes Mellitus in the Philippine National Formulary (PNF)
  October 14, 2022
• [Department Circular No. 2022 – 0291-A] Amendment to the Department Circular 2022-0291 “Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary”
  September 27, 2022
• [Department Circular No. 2022 – 0491] Nomination to the Health Technology Assessment Council (HTAC) Core Committee and Subcommittee Members
  September 23, 2022
• [Department Circular No. 2022 – 0486] Health Technology Assessment Council (HTAC) Recommendation for the Non-inclusion of Eribulin as Second-line Treatment of Metastatic Soft Tissue sarcoma (mSTS) the Philippine National Formulary (PNF)
  September 20, 2022
• [Advisory] Draft Department Memorandum on the Methodology of PEMDL Draft Interim Guidelines on the Process and Methods for the Selection of Medical Devices for Inclusion in the Philippine Essential Medical Device List (PEMDL) for Comments until 21 September 2022
  September 14, 2022
• [Department Memorandum No. 2022- 0379] Updated Checklist of Requirements for the Health Technology Assessment of COVID-19 Health Technologies to be referred by the Disease Prevention and Control Bureau (DPCB) and National Vaccine Operations Center (NVOC)
  September 2, 2022
• [Department Circular No. 2022- 0400] Change in the Generic Name of “Nicotine Polacrilex Medicated Chewing Gum” in the Philippine National Formulary (PNF) to “Nicotine”
  August 4, 2022
• [Department Personnel No. 2022- 2048] Creation of a Screening Committee for the Appointment of Health Technology Assessment Committee (HTAC) Members
  June 13, 2022
• [Department Circular No. 2022- 0288] Nomination to the Health Technology Assessment Council (HTAC) Social Anthropologist Core Committee Member
  June 10, 2022
• [Department Circular No. 2022- 0291] Health Technology Assessment Council (HTAC) Recommendation to include Potassium Citrate 15 mEq Extended Release (ER) Tablet in the Philippine National Formulary
  June 6, 2022
• [Department Circular No. 2022- 0257] Changes to the Topic Nomination and Appeals Processes of the Philippine HTA Process Guide
  May 27, 2022
• [Department Circular No. 2022- 0254] Updates on the HTAC processing of Minor Inclusion Application
  May 20, 2022
• [Department Personnel No. 2022- 2780 – A] Amendment to the Department Personnel Order No. 2021-2780 Entitled “Creation of the Pool of Clinical Experts for Consultation on the Evaluation of Assessment Topics” to Include Expert Advisory Committee as Additional Experts
  May 17, 2022
• [Department Personnel Order No. 2022- 1245] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Drugs
  May 10, 2022
• [Department Personnel Order No. 2022- 1102] Authority for Select Department of Health (DOH) Personnel to conduct a Hybrid Workshop on the Development of Guidelines in the Creation of the Philippine Essential Medical Device List (PEMDL) on April 22, 2022 in Metro Manila,
  April 7, 2022
• [Department Circular No. 2022- 0183] Opening of the 2022 Call for topic nomination
  April 1, 2022
• [Department Circular No. 2022- 0164] Health Technology Assessment Council (HTAC) Recommendation for reinclusion of vasopressin 20 iU/ml (IM/IV) in the Philippine National Formulary
  March 23, 2022
• [Department Circular No. 2022- 0074] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Drugs
  February 9, 2022
• [Department Circular No. 2022- 0015] Health Technology Assessment Council (HTAC) Recommendation to Include Sambong 250mg Tablet in the Philippine National Formulary
  January 21, 2022
• [Department Personnel Order No. 2021-3184] Appointment of the New Member of the Health Technology Assessment Council Subcommittee on Preventive and Promotive Health
  January 5, 2022

2021 Issuances

• [Department Personnel Order No. 2021-2780] Creation of Pool of Clinical Experts for Consultation on the Evaluation of Assessment Topics
  December 10, 2021
• [Department Circular No. 2021- 0471] Nomination to the Health Technology Assessment Council (HTAC) Subcommittee on Preventive and Promotive Health
  October 22, 2021
• [Department Circular No. 2021- 0468] Health Technology Assessment Council (HTAC) Recommendations on COVID-19 Vaccination of the Pediatric Population
  October 22, 2021
• [Signed by Secretary of Health] HTAC Recommendations on Booster and Additional Dose
  October 21, 2021
• [Signed by Secretary of Health] HTAC Interim Recommendations on Pediatric Vaccination for 2022 COVID-19 Vaccine Implementation
  October 15, 2021
• [Signed by Secretary of Health] September Updates on 2021 HTAC Recommendations for Rapid Antigen Tests
  October 12, 2021
• [Department Circular No. 2021- 0423] Inclusion of Dolutegravir (DTG) in the Philippine National Formulary (PNF)
  September 28, 2021
• [Signed by Secretary of Health] Letter of Endorsement for Dolutegravir for the Second-line Treatment for Treatment Experienced Adolescents and Adults Living with HIV
  September 21, 2021
• [Department Circular No. 2021- 0410] Inclusion of Two-Dose Inactivated Polio Vaccine (IPV) in the Philippine National Formulary (PNF)
  September 20, 2021
• [Department Circular No. 2021- 0400] Inclusion of Tenofovir/Lamivudine/Dolutegravir (TLD) in the Philippine National Formulary (PNF)
  September 10, 2021
• [Department Circular No. 2021- 0376] Interim Requirements for the Health technology Assessment (HTA) of Medical Devices
  September 3, 2021
• [Department Memorandum No. 2021- 0367] Health Technology Assessment Council’s (HTAC) Updated Recommendation on COVID-19 Vaccine Sinovac
  August 27, 2021
• [Department Circular No. 2021- 0337] Rescheduling of the Opening HTA Topic Nominations to March 2022
  August 17, 2021
• [Department Circular No. 2021- 0331] The Health Technology Assessment Council (HTAC) Releases Its Updated Evidence Summaries for COVID-19 Vaccine Assessments
  August 17, 2021
• MEMORANDUM- Request for Comments on Evaluation Framework for COVID-19 Vaccines (Version 2)
  August 16, 2021
• [Department Circular No. 2021- 0348] Coresia Vaccine Certificate Survey for Key Stakeholders
  August 10, 2021
• [Department Memorandum No. 2021- 0317] Non-inclusion of Pazopanib as a Second-line Treatment for Metastatic Soft Tissue (mSTS) Sarcoma in the Philippine National Formulary (PNF)
  July 21, 2021
• [Department Circular No. 2021- 0273] HTAC Issuance on Acceptance and processing of Health Technologies under Monitored Release with Phase IV Trial Data
  July 20, 2021
• [Department Memorandum No. 2021- 0294] Non-inclusion of Lapatinib in the Philippine National Formulary
  July 5, 2021
• [Department Memorandum No. 2021- 0264] Health Technology Assessment Council’s (HTAC) Recommendation on COVID-19 Vaccine Moderna
  June 9, 2021
• [Department Memorandum No. 2021- 0252] Health Technology Assessment Council’s (HTAC) Recommendations on RT-PCR and Rapid Antigen Testing for COVID-19
  June 1, 2021
• [Department Memorandum No. 2021- 0242] Inclusion of Nicotine Replacement Therapy (NRT) and Varenicline in the Primary Care Formulary
  May 27, 2021
• [Department Memorandum No. 2021- 0227] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  May 17, 2021
• [Department Memorandum No. 2021- 0199] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  April 23, 2021
• [Department Memorandum No. 2021- 0158] Inclusion of 0.1% Sodium Hyaluronate (15 ml) and 2.5% Peritoneal Dialysis Solution (2L and 5L) in the Philippine National Formulary
  April 5, 2021
• [Department Circular No. 2021- 0079] Health Technology Assessment Council’s (HTAC) Recommendations on health technologies requiring Full Certificate of Registration (CPR) from the Food and Drug Administration
  March 5, 2021
• [Department Memorandum No. 2021- 0075] Compliance to Dissemination of the Recommendations of the Health Technology Assessment Council (HTAC)
  February 26, 2021
• [Department Memorandum No. 2021- 0097] Health Technology Assessment Council’s (HTAC) Recommendations on COVID-19 Health Technologies
  February 26, 2021
• [Memo to DOH Internal Offices] Acknowledgement of Comments_Concurrence on COVID-19 Vaccines Evaluation Framework
  February 15, 2021
• [Department Memorandum No. 2021- 0079] Endorsement of Topic Submissions from National Health Programs for HTA
  February 10, 2021
• [Department Memorandum No. 2021- 0079] Endorsement of Topic Submissions from National Health Programs for Health Technology Assessment
  February 10, 2021
• [DOH Department Circular] Submission of Data of COVID-19 Vaccines under EUA
  February 2, 2021

2020 Issuances

• [Memo to DOH Internal Offices] Consultation for COVID-19 Vaccines Evaluation Framework.
  December 28, 2020
• Memo on the Acceptance of Minor Inclusions in the Philippine National Formulary (PNF) for Health Technology Assessment (HTA) Following the PNF System for Drugs
  November 18, 2020
• Extension of Topic Nomination (Existing Health Technologies) for Health Technology Assessment until 10 November 2020
  September 21, 2020
• [Advisory] Consultative Meeting for Administrative Order 2020-0041
  March 11, 2020
• [Department Circular No. 2020-0011] Non-Acceptance of Requests for Exemption from the Philippine National Formulary
  January 23, 2020